Plain-English translation of NCT07301814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new imaging scan called PET/MR or PET/CT that uses a special radioactive tracer to find cancer cells in people with stomach cancer, pancreatic cancer, bile duct cancer, esophageal cancer, and other tumors. The scan targets a specific protein called CLDN18.2 that appears on these cancer cells. Researchers want to see if this imaging approach can help doctors better identify tumors, predict how patients will respond to treatment, and decide which patients should receive targeted cancer therapies like Zolbetuximab.
Current cancer imaging tests don't always show all the cancer cells or help doctors predict which treatments will work best for each patient. This new imaging scan could fill that gap by giving doctors a clearer picture of cancer in the body and helping them choose the right treatment for each person.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will receive an injection of a radioactive tracer and then undergo a PET/MR or PET/CT imaging scan — a type of detailed picture that shows where cancer cells are located in your body. Healthy volunteers will also have blood tests to track how the tracer moves through your body and is cleared safely. The study compares these new imaging results to standard imaging tests you may have already had and to biopsies to determine how accurate and helpful the new scan is for cancer detection and treatment planning.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China